Smith Group Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Smith Group Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-26,890	Closed	-$218K	–	501
2016 Q3	$218K	Hold	26,890	–	–	0.01%	246
2016 Q2	$210K	Sell	26,890 -100	-0.4%	-$858	0.01%	246
2016 Q1	$208K	Sell	26,990 -95,510	-78%	-$700K	0.01%	213
2015 Q4	$1.32M	Sell	122,500 -19,010	-13%	-$173K	0.04%	161
2015 Q3	$978K	Buy	+141,510	New	+$1.15M	0.04%	165

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Smith Group Asset Management's ACHN Position: Q4 2016 in Review

Smith Group Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 26,890 shares — an estimated $218K sold.

Smith Group Asset Management first reported a position in ACHN in Q3 2015 and held it in 5 quarters. The position peaked at $1.32M in Q4 2015. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

Smith Group Asset Management reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Smith Group Asset Management sold 26,890 Achillion Pharmaceuticals shares in Q4 2016, an estimated $218K.
Smith Group Asset Management first reported a position in Achillion Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Smith Group Asset Management's Achillion Pharmaceuticals position peaked at $1.32M in Q4 2015.
140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Smith Group Asset Management's 13F filing for Q4 2016, filed 31 Jan 2017.